A NIR-Ⅱ fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer
Cancer Letters · 2026-05 · 646 · 218429
DOI: 10.1016/j.canlet.2026.218429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-05. Verfasst von Yi-Yang Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer & Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, X…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Breast Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Yunnan Key Research and Development Program, Kunming Medical University.
Abstract (Originalsprache)
The evaluation of therapeutic response to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer currently relies on anatomical imaging, which suffers from significant delays. To enable early and direct visualization of drug activity, we developed a near-infrared-II (NIR-II) fluorescent molecular probe, HSA-ICi, by conjugating a CDK4/6 inhibitor (Palbociclib or Ribociclib) with ICG and facilitating its self-assembly with human serum albumin. This probe demonstrated specific targeting to the CDK4/6-cyclin D complex, excellent biocompatibility, and high tumor accumulation in preclinical models. Crucially, HSA-ICi allowed non-invasive monitoring of pharmacodynamic response: a significant decrease in tumor fluorescence signal was detected via NIR-II imaging as early as one week after treatment initiation, preceding any measurable change in tumor volume by caliper or magnetic resonance imaging (MRI). This early signal reduction correlated with decreased pRB and Ki-67 expression in tumor tissues. Furthermore, the probe could distinguish between CDK4/6 inhibitor-sensitive and -resistant tumors, with resistant models showing a consistently low signal. Our findings establish HSA-ICi as a promising tool for the early assessment of therapeutic efficacy and the identification of resistance, potentially facilitating timely treatment adaptation for patients with HR+/HER2-breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer & Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen Univ…
- The Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking U…
Förderung
- National Natural Science Foundation of China
- Yunnan Key Research and Development Program
- Kunming Medical University
Zitieren
APA
Gao, Y. Y., Lou, K. L., Lin, L. L., Li, C. X., Lin, S. J., Chen, Y. X., Chen, H. Y., Bai, J. W., & Zhang, G. J. (2026). A NIR-Ⅱ fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer. Cancer Letters, 646, 218429. https://doi.org/10.1016/j.canlet.2026.218429
Vancouver
Gao YY, Lou KL, Lin LL, Li CX, Lin SJ, Chen YX, et al. A NIR-Ⅱ fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer. Cancer Letters. 2026;646:218429. doi:10.1016/j.canlet.2026.218429
BibTeX
@article{Gao2026,
author = {Gao, Yi-Yang and Lou, Kang-Liang and Lin, Lin-Ling and Li, Cheng-Xi and Lin, Sheng-Jie and Chen, Yi-Xin and Chen, Hong-Yu and Bai, Jing-Wen and Zhang, Guo-Jun},
title = {A NIR-Ⅱ fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer},
journal = {Cancer Letters},
year = {2026},
volume = {646},
pages = {218429},
doi = {10.1016/j.canlet.2026.218429}
}
EUVIMED